Citations

Clear

626 citation(s) found for "Mehta, SH".

Identification of fucosylated Fetuin‐A as a potential biomarker for cholangiocarcinoma
Betesh, Lucy, Comunale, Mary Ann , Wang, Mengjun , Liang, Hongyan , Hafner, Julie, Karabudak, Aykan , Giama, Nasra H., Moser, Catherine D., Miyoshi, Eiji , Roberts, Lewis R. , Block, Timothy M. , Mehta, Anand S. , Mehta, Anand , Roberts, Lewis R

Mayo Clinic

PROTEOMICS – Clinical Applications | May 31, 2017 | Volume: 11 | Issue: 9-10 | Pages: No page available

10.1002/prca.201600141 | PMID 28561948 Get It

PurposeCholangiocarcinoma (CCA) is a malignancy of the bile ducts. The purpose of this discovery study was to identify effective serum markers for surveillance of cholangiocarcinoma.Experimental designUsing a glycomic method, patients with CCA were determined to have increased levels of alpha‐1,3 and alpha‐1,6 linked fucosylated glycan. Proteomic analysis of the serum fucosylated proteome identified proteins such as alpha‐2‐macroglobulin, kininogen, hemopexin, fetuin‐A, alpha‐1 anti‐trypsin, and ceruloplasmin as being hyperfucosylated in HCC. The levels of these glycoproteins in 109 patients with CCA, primary sclerosing cholangitis (PSC), and control patients were compared to the performance of CA‐19‐9, the current “gold standard” assay for cholangiocarcinoma.ResultsFucosylated Fetuin‐A (fc‐Fetuin‐A) had the best ability to differentiate CCA from PSC, with an AUROC of 0.812 or 0.8665 at differentiating CCA from those with PSC or other liver disease. CA‐19‐9 had poor ability to differentiate PSC from cholangiocarcinoma (AUROC of 0.625).Conclusion and clinical relevanceUsing glycomic and proteomic methods we identified a set of proteins that contain altered glycan in the sera of those with CCA. One of these proteins, fucosylated Fetuin‐A may have value in the surveillance of people at risk for the development of cholangiocarcinoma.
Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
Won, Minhee , Blumenthal, Deborah T. , Vogelbaum, Michael A. , Colman, Howard, Jenkins, Robert B. , Chakravarti, Arnab , Brown, Paul D. , Jaeckle, Kurt A. , Schiff, David , Dignam, James J., Atkins, James N., Brachman, David, Werner‐Wasik, Maria, Komaki, Ritsuko , Mehta, Minesh P. , Aldape, Kenneth , Sulman, Erik P. , Colman, Howard , Jeraj, Robert , Gilbert, Mark R. , Mehta, Minesh P

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 31 | Issue: 18_suppl | Pages: LBA2010-LBA2010

10.1200/jco.2013.31.18_suppl.lba2010 Get It

LBA2010 Background: RTOG 0825 evaluated the addition of BEV to standard CRT in the treatment of GBM and included molecular stratification that assessed the degree of mesenchymal (MES) gene enrichment. We investigated the ability of the MES signature to predict response to BEV. Methods: Sufficient FFPE tissue for molecular analysis was available for 650 registered, eligible patients. TaqMan PCR was performed prospectively using the molecular stratifier on all patients and an expanded 43 member MES set on 234 cases. A subset of specimens was subjected to whole genome expression profiling (GEP). Predictive models were evaluated for their ability to predict survival (overall, OS, and progression-free, PFS) in the training cohort of the BEV arm after adjusting for prognostic factors and treatment arm. Unsupervised clustering of GEP data was used to identify molecular subsets and gene set enrichment analysis (GSEA) performed to evaluate for MES enrichment. Results: We observed a significant association between increasing MES signature and worse PFS and OS in the BEV arm (p=0.036 and p=0.032, respectively). Based on the association between high MES expression and poor outcome in the BEV arm, we sought to optimize a predictor using an expanded set of MES genes. Unbiased gene selection from a total of 43 genes followed by radial basis machine modeling identified a 10-gene predictor of outcome in the BEV arm (p<0.001/HR 4.04 for OS and p<0.001/HR 2.21 for PFS). To further support the association of MES enrichment and poor outcome in the BEV arm, we performed GEP. Unsupervised clustering identified a subtype of tumors with MES enrichment associated with the 10-gene predictor survival probability (p=0.0124, t-test). Ongoing studies will determine the extent to which this represents a predictive marker for BEV. Conclusions: We developed a 10-gene predictor specific to BEV treatment and suitable for FFPE that may serve to identify subsets of patients with newly diagnosed GBM who benefit from BEV. Supported by RTOG grant U10 CA21661, CCOP grant U10 CA37422, and Brain SPORE P50 CA127001 from the NCI and Genentech. Clinical trial information: NCT00884741.
RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
Dignam, James J., Won, Minhee , Blumenthal, Deborah T. , Vogelbaum, Michael A. , Aldape, Kenneth , Colman, Howard, Chakravarti, Arnab , Brown, Paul D. , Jaeckle, Kurt A. , Schiff, David , Atkins, James N., Brachman, David, Werner‐Wasik, Maria, Komaki, Ritsuko , Mehta, Minesh P. , Gilbert, Mark R. , Colman, Howard , Jeraj, Robert , Armstrong, Terri S. , Wefel, Jeffrey S. , Sulman, Erik P. , Mehta, Minesh P

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 31 | Issue: 18_suppl | Pages: 1-1

10.1200/jco.2013.31.18_suppl.1 Get It

1 Background: Chemoradiation (CRT) with temozolomide (TMZ/RT→TMZ) is the standard of care for newly diagnosed GBM. This trial determined if the addition of Bev to standard CRT improves survival (OS) or progression-free survival (PFS) in newly diagnosed GBM. Methods: This phase III trial was conducted by the RTOG, NCCTG, and ECOG. Neurologically stable pts > 18 yrs with KPS ≥ 60, and > 1cm3 tumor tissue block, were randomized to Arm 1: standard CRT + placebo or Arm 2: standard CRT plus Bev (10 mg/kg iv q 2wks). Experimental treatment began at wk 4 of radiation then thru 6-12 cycles of maintenance chemotherapy. Protocol specified co-primary endpoints were OS and PFS, with significance levels of .023 and .002, respectively. At progression, treatment was unblinded and pts allowed to crossover or continue Bev. Symptom, QOL and neurocognitive (NCF) testing was performed in the majority of pts. Secondary analyses evaluated impact of MGMT methylation (meth) and prognostic 9 gene signature status. Results: From 978 registered pts, 637 were randomized. Inadequate tissue (n=105) and blood on imaging (n=40) were key reasons for non-randomization. No difference was found between arms for OS (median 16.1 vs. 15.7 mo, p = 0.11). PFS was extended for Arm 2 (7.3 vs. 10.7 mo, p = 0.004). Pts with MGMT meth had superior OS (23.2 vs. 14.3 mo, p < 0.001) and PFS (14.1 vs. 8.2 mo, p < 0.001). Neither the 9 gene signature nor MGMT predicted selective benefit for Bev treatment, but best prognosis pts (MGMT meth, favorable 9-gene), had a worse survival trend with Bev (15.7 vs 25 mo p = 0.08). To date, 128 pts were unblinded on Arm 1 (salvage Bev in 86) and 87 pts on Arm 2 (continued Bev in 39). Increased grade ≥ 3 toxicity was seen with Bev, mostly neutropenia, hypertension, and DVT/PE. Conclusions: The addition of Bev for newly diagnosed GBM did not improve OS, did improve PFS but did not reach the significance criterion. MGMT and 9 gene profile did not identify selective benefit, but risk subset results suggested strongly against the upfront use of Bev in the best prognosis pts. Full interpretation of the PFS results incorporating symptom burden, QOL, and NCF is ongoing. Support: NCI U10 CA 21661, U10 CA37422, and Genentech. Clinical trial information: NCT00884741.
RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas
Vogelbaum, Michael A. , Brown, Paul D. , Blumenthal, Deborah T. , Biggs, Christopher , Schultz, Carolyn J. , Berkey, Brian A. , Peereboom, David M. , Giannini, Caterina , Suh, John H. , Schultz, C., Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 1520-1520

10.1200/jco.2005.23.16_suppl.1520 Get It

RTOG 0525: Molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma.
Aldape, Ken, Wang, M., Colman, Howard , Jones, G. T., Chakravarti, Arnab , Long, Lihong, Diefes, Kristin, Heathcock, Lindsey, Jenkins, Rosalind E. , Gilbert, M. R., Group, Radiation Therapy Oncology, Sulman, Erik P. , Hegi, Monika E. , Colman, Howard , Mehta, Minesh P. , Andrews, David William , Jenkins, R., Schultz, Carl Johann , Group, Radiation Therapy Oncology

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 29 | Issue: 18_suppl | Pages: LBA2000-LBA2000

10.1200/jco.2011.29.18_suppl.lba2000 Get It

LBA2000 Background: Formalin-fixed, paraffin embedded GBM tumor tissue, adequate for conventional MGMT methylation analyses, was required for entry onto the RTOG 0525 clinical trial. Methods: Four prognostic biomarkers were evaluated on a training set of 220 retrospectively obtained GBM samples, consisting of IDH1 mutation, the glioma-CpG island methylator phenotype (G-CIMP), a microarray-based mRNA panel and a novel MGMT promoter methylation assay. For each biomarker, 2 (IDH1 and mRNA) or 3 subgroups (G-CIMP and MGMT) were defined based on associations with overall survival. All combinations (36 possible) of each of the 4 biomarker-derived subgroups were then defined and compared with survival data and then consolidated into 4 risk groups. Once created in the training set, this model was applied to the RTOG 0525 samples (n=763) for external validation. Results: Application of the molecular risk classification to RTOG 0525 samples (left table) showed a highly significant survival association (p<0.001). When compared to the recursive partitioning analysis (RPA, table on right), this composite molecular classifier better identified patients with long term survival and appears to improve resolution by revealing an additional distinct risk group. The molecular classifier was prognostic in each of the treatment arms individually. Conclusions: Four distinct biomarkers or biomarker panels were tested in GBM. These biomarkers were compared with clinical outcome in a training set to optimize a method to combine them into a classifier. This classifier was then validated on a large sample set from a large phase III clinical trial. This composite panel may represent an improvement over the existing RPA with respect to risk stratification of patients for GBM. Additionally, it has the potential to impact future clinical trial designs and provide enhanced opportunities for personalization of therapy for GBM. Support: NCI U10 CA2121661, U10 CA37422, P50 CA127001. [Table: see text]
A risk prediction score for acute kidney injury in the intensive care unit
Malhotra, Rakesh , Macedo, Etienne , Kim, Jihoon , Bouchard, Josée , Wynn, Susan, Li, Guangxi , Ohno‐Machado, Lucila , Mehta, Ravindra L. , Kashani, Kianoush , Mehta, Ravindra L , Macedo, Etienne , Li, Guangxi

Mayo Clinic

Nephrology Dialysis Transplantation | February 15, 2017 | Volume: 32 | Issue: 5 | Pages: 814-822

10.1093/ndt/gfx026 | PMID 28402551 Get It

Risk of Hypertension among First-Time Symptomatic Kidney Stone Formers
Kittanamongkolchai, Wonngarm , Mara, Kristin C. , Mehta, Ramila A. , Vaughan, Lisa E. , Đenić, Aleksandar , Knoedler, John, Knoedler, John J., Enders, Felicity , Lieske, John C. , Rule, Andrew D. , Denic, Aleksandar , Mara, Kristin C

Mayo Clinic

Clinical Journal of the American Society of Nephrology | February 1, 2017 | Volume: 12 | Issue: 3 | Pages: 476-482

10.2215/cjn.06600616 | PMID 28148559 Get It

Background and objectives Prior work has suggested a higher risk of hypertension in kidney stone formers but lacked disease validation and adjustment for potential confounders. Certain types of stone formers may also be at higher risk of hypertension. Design, setting, participants, & measurements In our study, incident symptomatic stone formers in Olmsted County from 2000 to 2011 were manually validated by chart review and age and sex matched to Olmsted County controls. We followed up patients through November 20, 2015. Hypertension was also validated by manual chart review, and the risk of hypertension in stone formers compared with controls was assessed both univariately and after adjusting for comorbidities. The risk of hypertension among different subtypes of stone formers was also evaluated. Results Among 3023 coded stone formers from 2000 to 2011, a total of 1515 were validated and matched to 1515 controls (mean age was 45 years old, and 56% were men). After excluding those with baseline hypertension (20% of stone formers and 18% of controls), 154 stone formers and 110 controls developed hypertension. Median follow-up time was 7.8 years in stone formers and 9.6 years in controls. Stone formers were found to have a higher risk of hypertension compared with controls (hazard ratio, 1.50; 95% confidence interval, 1.18 to 1.92), even after adjusting for age, sex, body mass index, serum creatinine, CKD, diabetes, gout, coronary artery disease, dyslipidemia, tobacco use, and alcohol abuse (hazard ratio, 1.58; 95% confidence interval, 1.12 to 2.21). Results were similar after excluding patients who were ever on a thiazide diuretic (hazard ratio, 1.65; 95% confidence interval, 1.16 to 2.38). Stone composition, radiographic stone burden, number of subsequent stone events, and stone removal surgeries were not associated with hypertension ( P >0.05 for all). Conclusions The risk of hypertension was higher after the first symptomatic kidney stone event. However, kidney stone severity, type, and treatment did not associate with hypertension.
Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient: 2016 update—executive summary
DeBlock, Heidi F., Erstad, Brian L. , Gray, Anthony, Jacobi, Judith , Jordan, Ché J., McGee, William T. , McManus, Claire, Meade, Maureen O. , Nix, Sean , Sands, Karen, Pino, Richard M. , Tescher, Ann, Arbour, Richard, Murray, Catherine Friederich, Mehta, Sangeeta , Tescher, Ann N, Murray, Michael J. , Patterson, Andrew J. , Rochwerg, Bram

Mayo Clinic

American Journal of Health-System Pharmacy | January 9, 2017 | Volume: 74 | Issue: 2 | Pages: 76-78

10.2146/ajhp160803 | PMID 28069681 Get It